Evercore initiated coverage of an immunology and inflammation drug developer at an outpeform, saying that the market is underpricing its odds for success.
Evercore ISI initiated coverage of Aclaris Therapeutics , a clinical stage biotech working on immunology and inflammation drugs, at an outperform, saying that the market is underpricing its odds for success heading into the release of clinical trial data. "We think the stock could trade up 300%+ on positive data , and down ~67% on negative data ," said analyst Gavin Clark-Gartner in a research note Tuesday.
It's a tough time for clean energy stocks right now, but Raymond James says one name can buck the downtrend
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Evercore ISI says buy this eyewear stock as it approaches a 'fundamental inflection year'Besides strong fundamentals, positive survey results and an attractive valuation make a compelling case for buying this stock, according to Evercore.
Consulte Mais informação »
Evercore ISI upgrades this electric vehicle maker, says it can become the next TeslaAnalyst Chris McNally upgraded Rivian Automotive to outperform from in line and raised his price target to $35.
Consulte Mais informação »
Seabrook Square development to add over 200 units of affordable rental housing in East AustinThe community will be located in the J.J. Seabrook neighborhood, named after Dr. John Jarvis Seabrook, a Black educator, pastor and community leader.
Consulte Mais informação »
NASA’s Perseverance Rover Captures 200-Foot-Wide Dust Devil Tearing Across MarsThe six-wheeled geologist spotted the twister as part of an atmospheric exploration of Jezero Crater. The lower portion of a Martian dust devil was captured moving along the western rim of Mars’ Jezero Crater by NASA’s Perseverance rover on August 30, 2023, the 899th Martian day, or sol, of the m
Consulte Mais informação »
Rod Wave’s ‘Nostalgia’ Notches Second Week Atop Billboard 200 ChartPlus: Doja Cat and Zach Bryan debut in top 10.
Consulte Mais informação »
The Rose Enters Billboard 200 For 1st Time With “DUAL”The Rose Enters Billboard 200 For 1st Time With “DUAL”
Consulte Mais informação »